Publications by authors named "Filipa Silva-Ferreira"
Article Synopsis
- The study aimed to evaluate the accuracy of three assays for measuring anti-infliximab antibodies (ADAs) in patients treated with infliximab, especially considering the impact of detectable infliximab levels on the results.
- Blood samples from 79 ulcerative colitis patients were tested using an in-house assay and two commercial kits (Immundiagnostik and Theradiag), revealing varying detection rates for ADAs, with Immundiagnostik performing better than Theradiag.
- The presence of infliximab affected ADA detection, particularly at lower concentrations, leading to potential inaccuracies in diagnosing and monitoring treatments if double-negative or double-positive results are misinterpreted.
Background: Immunogenicity to therapeutic proteins has been linked to loss of response by a large percentage of patients taking anti-tumor necrosis factor-alpha agents. Drug monitoring can be extremely useful, allowing physicians to adjust the therapeutic scheme individually. This article aims to systematically review the published data with respect to cutoff levels of infliximab (IFX) and adalimumab (ADA) and relate them to the methodology adopted for quantification of IFX and ADA levels and clinical outcomes.
View Article and Find Full Text PDF